JS Link, Inc. (KOSDAQ:127120)

South Korea · Delayed Price · Currency is KRW

33,000

+1,300 (4.10%)

At close: Sep 9, 2026

Market Cap	1.15T +126.0%
Revenue (ttm)	22.78B +51.3%
Net Income	-5.30B
EPS	-165.45
Shares Out	34.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,912
Open	32,250
Previous Close	31,700
Day's Range	31,700 - 33,250
52-Week Range	13,860 - 49,900
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About JS Link

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additio... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2000

Employees 84

Stock Exchange KOSDAQ

Ticker Symbol 127120

Full Company Profile

Financial Performance

In 2025, JS Link's revenue was 19.32 billion, an increase of 21.43% compared to the previous year's 15.91 billion. Losses were -16.45 billion, 52.2% more than in 2024.

Financial Statements